Revolution Medicines, Inc. (RVMDW) company profile
Close on Oct 30, 2026Market cap $41.00BP/E –Yield –
About Revolution Medicines
Biological Products, (No Diagnostic Substances), SIC 2836
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapeutics for cancer patients. The business concentrates on the discovery and clinical advancement of novel drug candidates aimed at critical oncogenic pathways driving cancer progression. Because the company currently has no products approved for commercial sale, its pipeline candidates remain under preclinical and clinical investigation. Consequently, its primary end beneficiaries are oncology patients, alongside research collaborators, licensing organizations, and healthcare institutions engaged in precision oncology drug development.
Revolution Medicines operates principally within the United States, carrying out its scientific research, development pipelines, and clinical trial programs across domestic healthcare sites. The company maintains its research, administrative, and clinical development infrastructure across facilities situated in Redwood City, California. The company's principal executive offices and headquarters are located at 700 Saginaw Drive, Redwood City, California 94063.
Summary of the business section of Revolution Medicines's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Revolution Medicines, Inc.
- Founded
- 2014
- Headquarters
- Redwood City, CA
- Address
- 700 Saginaw Dr 94063
- Phone
- (650) 481-6801
- Website
- revolutionmedicines.com
- Employees
- 883, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- RVMDW
- Other tickers
- RVMD
- Exchange
- Nasdaq
- IPO date
- Feb 13, 2020
- Shares outstanding
- 214M, Jul 31, 2026
- Public float
- $6.70B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1628171
- CUSIP
- 76155X118
- ISIN
- US76155X1182
- FIGI
- BBG01K4M90R2
- LEI
- 549300JU3X0LBCQ65892
- EIN
- 47-2029180
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mark A. Goldsmith | See Remarks, Director | 314,766 |
| Jeff Cislini | SVP & General Counsel | 51,776 |
| Anthony Mancini | See Remarks | 42,886 |
| Alan B. Sandler | Chief Development Officer | 53,204 |
| Stephen Michael Kelsey | See Remarks | 286,307 |
| Margaret A. Horn | Chief Operating Officer | 154,571 |
| Jack Anders | Chief Financial Officer | 123,208 |
| Xiaolin Wang | See Remarks | 116,063 |
| Lin Wei | Chief Medical Officer | 101,366 |
| Elizabeth M. Anderson | Director | 31,423 |
| Lorence H. Kim | Director | 10,136 |
| Sushil Patel | Director | 24,078 |
| Sandra Horning | Director | 97,765 |
| Flavia Borellini | Director | 26,215 |
| Alexis Borisy | Director | 2,340,075 |
| Frank Clyburn | Director | 10,929 |
| Thilo Schroeder | Director | 7,601,087 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $14.67M | $37.06M | $4.52M | $201 | $125 |
| FY2024 | $10.08M | $20.33M | $4.30M | $110 | $117 |
| FY2023 | $10.41M | $14.00M | $3.77M | $72 | $114 |
| FY2022 | $7.22M | $8.64M | $2.48M | $60 | $110 |
| FY2021 | $7.83M | -$3.47M | $2.37M | $64 | $125 |
| FY2020 | $2.39M | $25.71M | $1.26M | $137 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Mark A. Goldsmith, M.D., Ph.D. President and Chief Executive Officer | $812.50K | $3.97M | $9.00M | $889.70K | $7.00K | $14.67M | +46% |
| Jack Anders Chief Financial Officer | $523.33K | $831.10K | $1.88M | $343.80K | $7.00K | $3.59M | +9% |
| Stephen M. Kelsey, M.D., FRCP, FRCPath President, Research and Development | $625.83K | $1.49M | $3.38M | $461.20K | $7.00K | $5.96M | +0% |
| Margaret Horn, J.D. Chief Operating Officer | $582.67K | $1.17M | $2.64M | $426.50K | $7.00K | $4.82M | -1% |
| Jeffrey Cislini General Counsel and Secretary | $523.75K | $896.28K | $2.03M | $261.00K | $7.00K | $3.72M | +36% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 13, 2020
- Offer price
- $17.00
- Securities offered
- 14,000,000
- Gross proceeds
- $238.00M
- Exchange
- Nasdaq
- First trading day
- Feb 13, 2020
- First-day close
- $28.90+70.0%
- Lock-up ends (est.)
- Aug 11, 2020
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 883 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 15, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 9, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 29, 2023 | Merger vote | Definitive merger proxy statement |
| Sep 13, 2023 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 13, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 6, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |